Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.49591
Abstract: Key Points Question Is tumor mutational burden (TMB) associated with outcomes among patients with locally advanced unresectable non–small cell lung cancer (NSCLC) treated with definitive chemoradiation and consolidative durvalumab? Findings In this cohort study of… read more here.
Keywords: locally advanced; free survival; durvalumab; progression free ... See more keywords
Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4593
Abstract: Agents targeting the programmed cell death‐1 pathway have demonstrated encouraging activity across multiple solid tumor types. The dose expansion phase of this phase I study evaluated the safety, tolerability, and antitumor activity of durvalumab monotherapy,… read more here.
Keywords: head neck; durvalumab; tolerability; biliary tract ... See more keywords
Durvalumab and multiple sclerosis: a causal link or simple unmasking?
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Clinical Pharmacology"
DOI: 10.1007/s00228-020-02959-0
Abstract: Dear Sirs, Immune checkpoint inhibitors (ICIs) became the new milestone of the immune-oncology therapy. This family includes three drug classes: anti-cytotoxic T lymphocyte–associated protein4 (CTLA4), anti-programmed cell death 1 (PD-1), and anti-programmed death-ligand 1 (PD-L1).… read more here.
Keywords: durvalumab; anti; multiple sclerosis; therapy ... See more keywords
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-024-04743-8
Abstract: Durvalumab in combination with gemcitabine/cisplatin has shown a favorable benefit-risk profile in the TOPAZ-1 study for advanced biliary tract cancers (BTC). This analysis evaluated the population pharmacokinetics (PopPK) of durvalumab, and exposure-response for efficacy and… read more here.
Keywords: treatment; analysis; exposure response; population ... See more keywords
Durvalumab: A Review in Extensive-Stage SCLC
Sign Up to like & getrecommendations! Published in 2021 at "Targeted Oncology"
DOI: 10.1007/s11523-021-00843-0
Abstract: Durvalumab (IMFINZI®), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small… read more here.
Keywords: chemotherapy; combination; durvalumab; extensive stage ... See more keywords
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01796-6
Abstract: Cancer immunotherapy represents one of the most important innovations in modern medicine. Durvalumab is an anti-programmed cell death ligand 1 (PDL-1) agent which is currently under investigation in several studies in combination with the anti-cytotoxic… read more here.
Keywords: tremelimumab; solid tumors; durvalumab; plus tremelimumab ... See more keywords
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
Sign Up to like & getrecommendations! Published in 2022 at "ESMO Open"
DOI: 10.1016/j.esmoop.2022.100385
Abstract: Background We evaluated the efficacy of adjuvant durvalumab after neoadjuvant concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC). Patients and methods This randomized, double-blind, phase II study included patients with ESCC who… read more here.
Keywords: durvalumab; cell carcinoma; adjuvant durvalumab; ccrt ... See more keywords
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Sign Up to like & getrecommendations! Published in 2022 at "ESMO open"
DOI: 10.1016/j.esmoop.2022.100408
Abstract: BACKGROUND In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab plus… read more here.
Keywords: durvalumab; durvalumab plus; tremelimumab plus; plus tremelimumab ... See more keywords
Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.05.011
Abstract: INTRODUCTION Recently updated three-year survival data from the PACIFIC trial showed that durvalumab consolidation therapy improved OS rates versus placebo for patients with unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy. Considering the… read more here.
Keywords: consolidation therapy; durvalumab; cost; cost effectiveness ... See more keywords
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
Sign Up to like & getrecommendations! Published in 2022 at "Lung cancer"
DOI: 10.1016/j.lungcan.2022.02.003
Abstract: INTRODUCTION Immune-mediated adverse events (imAEs), including all-cause immune-mediated pneumonitis, were reported in approximately 25% of patients in the placebo-controlled, phase III PACIFIC trial of durvalumab monotherapy (for up to 12 months) in patients with unresectable, stage… read more here.
Keywords: durvalumab; imaes; pneumonitis; non pneumonitis ... See more keywords
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
Sign Up to like & getrecommendations! Published in 2025 at "Nature Medicine"
DOI: 10.1038/s41591-025-03746-z
Abstract: In the phase II NeoCOAST-2 platform study, 202 patients with untreated, resectable stage IIA–IIIB non-small-cell lung cancer (NSCLC) were randomized to receive neoadjuvant durvalumab plus platinum-doublet chemotherapy with oleclumab, a CD73 inhibitor (Arm 1), or… read more here.
Keywords: non small; durvalumab plus; small cell; chemotherapy ... See more keywords